REFFERAL FORM FOR EXAMINATION SYSTEMIC AND DENTAL RISK DURATION OF CONTRAINDICATION...
cz/ en/ de

ONCOLOGY

High risk
    Bisphosphonate or denosumab therapy
Medium risk
    CHT with high risk of developing FN (>20 %) *

    CHT with medium risk of developing FN (10-20 %) and the presence of other risk factors in the patient or related to anticancer treatment, increasing the risk of developing FN or complicating its course *

    Risk factors:
  • presence of severe internal comorbidities
  • age ≥ 65 years
  • poor nutritional status of the patient
  • tumour infiltration of the bone marrow
  • previous RT to a large part of the axial bone structure
  • primary immunodeficiency
  • pre-medication
  • lack of patient compliance
  • previous episode of FN
  • concomitant radiotherapy
Low risk
    CHT with low risk of developing FN (< 10 %) in the presence of RF
The issue of radiotherapy in the orofacial area and haematological malignancies is prepared separately.

* The risk of developing FN is determined by the referring oncologist based on the chosen therapy and the patient's condition, e.g. according to:

https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf

CHT - Chemotherapy
FN - Febrile Neutropenie
RF - Risk factors